Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies Corporation announced its participation in the Cowen 41^st Annual Healthcare Conference, scheduled for March 2, 2021. The company will engage in a fireside chat at 7:30 a.m. PT / 10:30 a.m. ET.

Interested parties can access a live and archived webcast on their website. Adaptive focuses on utilizing the adaptive immune system to develop clinical products for diagnosing and treating diseases, with a strong emphasis on precision and individual patient care.

SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Cowen 41^st Annual Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, March 2^nd at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies 
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

FAQ

What is the date and time of Adaptive Biotechnologies' fireside chat at the Cowen 41st Annual Healthcare Conference?

The fireside chat will take place on March 2, 2021, at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time.

How can I access the webcast of Adaptive Biotechnologies' presentation at the conference?

You can access the live and archived webcast on the 'Investors' section of Adaptive Biotechnologies' website.

What is the focus of Adaptive Biotechnologies as a company?

Adaptive Biotechnologies focuses on harnessing the adaptive immune system to create products for diagnosing and treating diseases.

What types of diseases does Adaptive Biotechnologies aim to target with its products?

The company targets diseases such as cancer, autoimmune conditions, and infectious diseases.

What products does Adaptive Biotechnologies currently offer?

Adaptive Biotechnologies has three commercial products and a robust clinical pipeline aimed at immune-driven clinical applications.